Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Inclusion Criteria

• •age ≥18 years
• •HIV-2 mono infection, confirmed by ELISA and Western Blot test or Immunoblot,
• •antiretroviral treatment-naive, whatever the duration and indication of prior treatments,
• •indication to treatment, with at least one of the following criteria : type B or C events, CD4 lymphocytes count below 500/mm3 at screening-visit or CD4 lymphocytes count decrease of at least 50 cell/µL/year over the last 3 years with the last CD4 lymphocytes count within -/+ 10 % of the nadir, plasma HIV-2 RNA load over or equal to 100 copies/mL at screening-visit,
• •Pneumocystis prophylaxis if CD4 lymphocytes count below 200/mm3, combined to a toxoplasmosis prophylaxis in case of a positive toxoplasmosis serology,
• •French residency for at least one year,
• •Written informed consent, signed by the participant and the investigator (at the latest on the screening-visit and prior any study related intervention)
• •Affiliate or beneficiary of a social security system (State Medical Assistance is not a social security scheme).